IDRSF
Idorsia Ltd·Healthcare
4.32
1.370%(−0.06)
Market ClosedLast Updated: — ET
52W L: $1.0052W H: $5.82
IDRSF NEWS
globenewswire.com
1d ago
Idorsia issues invitation to the 2026 Annual General Meeting of Shareholders
Allschwil, Switzerland – April 10, 2026 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2025, will be held on Wednesday, May 6, 2026, at 14.00 CEST at the Congress Center, Messe Basel, Switzerland.
globenewswire.com
2d ago
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
Allschwil, Switzerland – April 9, 2026 Idorsia Ltd (SIX: IDIA) announces the appointment of Dr Amer Joseph as Executive Vice President, Chief Medical Officer (CMO) & Head of Global Clinical Development, effective May 1, 2026. He succeeds Dr Alberto Gimona, who is retiring.
seekingalpha.com
Mar 31
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders Transcript
globenewswire.com
Mar 24
Idorsia announces the nomination of three candidates for election to the Board of Directors
Allschwil, Switzerland – March 24, 2026 Idorsia Ltd (SIX: IDIA) announces that the Board of Directors will propose three candidates for election to the Board at the upcoming Annual General Meeting of Shareholders: Natalia Misciattelli, Chief Executive Officer and member of the Board of Directors at AAVantgarde Bio; Gabriel Baertschi, Chief Executive Officer of Grünenthal; and André C. Muller, former Chief Executive Officer of Idorsia.
globenewswire.com
Mar 16
Idorsia announces management change
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 16, 2026 Idorsia Ltd (SIX: IDIA) announces that Dr Srishti Gupta and the Board of Idorsia have mutually agreed that Srishti will step down from her role as Chief Executive Officer (CEO).
globenewswire.com
Mar 10
Idorsia expands QUVIVIQ's global footprint through new partnership with Pharmalink
Allschwil, Switzerland – March 10, 2026 Idorsia Ltd (SIX: IDIA) has entered into an exclusive agreement with Pharmalink Drug Store L.L.C for the distribution and commercialization of QUVIVIQ™ (daridorexant) – its treatment for adults with insomnia – across the United Arab Emirates (UAE), Kuwait, Qatar, Oman, and Bahrain.
